Study guide
9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs
Key Takeaways Explain This Topic AI
The Vaughan-Williams classification categorizes antiarrhythmics by their electrophysiological actions: Class I agents block voltage-gated cardiac sodium channels ( N a V 1.5 Na_V1.5 N a V 1.5 ), with Class Ia (procainamide, quinidine) prolonging action potential duration (APD) and repolarization, Class Ib (lidocaine, mexiletine) shortening APD especially in depolarized or ischemic ventricular myocardium, and Class Ic (flecainide, propafenone) profoundly slowing conduction velocity ( d V / d t max dV/dt_{\max} d V / d t m a x ) with neutral effects on APD.
Amiodarone (Class III) is a broad-spectrum, highly lipophilic antiarrhythmic with an enormous volume of distribution (about 60 L/kg 60\text{ L/kg} 60 L/kg , several thousand litres) and prolonged elimination half-life (30 to 60 days); despite prolonging the QTc interval, it exhibits a remarkably low risk of Torsades de Pointes (<1%) due to concurrent non-competitive beta-blockade, calcium channel blockade, and uniform prolongation of transmural refractoriness, but produces significant non-cardiac toxicities including pulmonary fibrosis, thyroid dysfunction, and corneal microdeposits.
Adenosine acts on cardiac A 1 A_1 A 1 purinergic receptors coupled to G i G_i G i , opening acetylcholine/adenosine-sensitive inward-rectifying potassium channels ( I K,Ado I_{\text{K,Ado}} I K,Ado ) and inhibiting L-type calcium currents ( I Ca,L I_{\text{Ca,L}} I Ca,L ) to transiently hyperpolarize the atrioventricular (AV) node and produce complete conduction block; its ultra-short half-life ( < 10 seconds <10\text{ seconds} < 10 seconds ) is governed by rapid uptake into erythrocytes and vascular endothelium, followed by intracellular deamination by adenosine deaminase.
Sodium nitroprusside releases nitric oxide (NO) spontaneously and non-enzymatically, causing balanced arterial and venous dilation; prolonged or high-dose infusions generate toxic cyanide ions that inhibit mitochondrial cytochrome c oxidase (Complex IV), arresting aerobic respiration and presenting with unexplained lactic acidosis, tachyphylaxis, and elevated mixed venous oxygen saturation ( S v O 2 Sv\text{O}_2 S v O 2 ), treated with hydroxocobalamin, sodium thiosulfate, or sodium nitrite.
Clevidipine and esmolol are ultra-short-acting, titratable cardiovascular agents cleared independently of organ perfusion: clevidipine is a vascular-selective dihydropyridine calcium channel blocker ( t 1 / 2 = 1 − 2 minutes t_{1/2} = 1-2\text{ minutes} t 1/2 = 1 − 2 minutes ) formulated in a 20% lipid emulsion and hydrolyzed by blood and tissue esterases, while esmolol is a cardioselective β 1 \beta_1 β 1 -adrenergic antagonist ( t 1 / 2 ≈ 9 minutes t_{1/2} \approx 9\text{ minutes} t 1/2 ≈ 9 minutes ) metabolized rapidly by red blood cell cytoplasmic esterases.
Last updated: October 2026
9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs
Cardiovascular pharmacotherapy during the perioperative period requires nuanced control over myocardial electrophysiology, cardiac rhythm, and vascular tone. Selecting the correct intervention requires an exact understanding of cardiac action potential phases, ion channel dynamics, receptor-effector coupling, and metabolic pathways governing drug onset and termination.
1. The Vaughan-Williams Classification of Antiarrhythmic Drugs
The Vaughan-Williams classification organizes antiarrhythmic agents into four primary classes based on their predominant electrophysiological mechanism on the cardiac action potential. [ CARDIAC ACTION POTENTIAL & DRUG CLASSES ]
- Millivolts (mV)
- +20 | 1 (Transient outward K+ current, I_to)
- | /---\ 2 (Plateau phase: inward I_Ca,L vs outward I_Kr/I_Ks)
- 0 | / \===================\
- | 0 / \
-20 | (Phase 0: \ 3 (Phase 3 repolarization:
- | Inward I_Na) \ outward I_Kr, I_Ks)
- 40 | | \
- | / \
- 60 | / \____________________ 4 (Resting potential)
- 80 |_ / Phase 4: I_K1 (and I_f in nodal tissue)
- +-------------------------------------------------------------> Time
- Class I: Sodium Channel Blockers (Phase 0 dV/dt_max)
- Ia (Quinidine, Procainamide): Intermediate dissociation; prolongs APD & ERP
- Ib (Lidocaine, Mexiletine): Rapid dissociation; shortens APD in ischemic myocardium
- Ic (Flecainide, Propafenone): Slow dissociation; marked Phase 0 depression, neutral APD
Class II: Beta-Blockers (SA/AV nodal Phase 4 slope reduction & decreased I_Ca,L)
- Class III: Potassium Channel Blockers (Inhibit Phase 3 I_Kr/I_Ks -> prolongs APD & QTc)
- Amiodarone, Sotalol, Ibutilide, Dronedarone
- Class IV: Non-Dihydropyridine Calcium Channel Blockers (Inhibit L-type Ca2+ in SA/AV nodes)
- Verapamil, Diltiazem
- Class I: Voltage-Gated Sodium Channel Blockers ( N a V 1.5 Na_V1.5 N a V 1.5 )
Class I agents bind to the pore-forming alpha-subunit of the cardiac voltage-gated sodium channel ( N a V 1.5 Na_V1.5 N a V 1.5 ), depressing the maximum rate of Phase 0 depolarization ( d V / d t max dV/dt_{\max} d V / d t m a x ). They are subdivided into Ia, Ib, and Ic based on their channel binding kinetics and their net effect on the action potential duration (APD) and effective refractory period (ERP):
Class Ia (Procainamide, Quinidine, Disopyramide):
Kinetics: Intermediate onset and dissociation kinetics (time constant of recovery τ = 1 − 8 seconds \tau = 1 - 8\text{ seconds} τ = 1 − 8 seconds ).
Electrophysiology: Moderately depress Phase 0 d V / d t max dV/dt_{\max} d V / d t m a x , slowing intra-atrial, intraventricular, and His-Purkinje conduction. Uniquely, Class Ia agents also block outward delayed rectifier potassium currents ( I Kr I_{\text{Kr}} I Kr ), which prolongs Phase 3 repolarization, APD, and the ERP . On the surface ECG, they cause widening of the QRS complex and prolongation of the QT interval, carrying a risk of torsades de pointes.
Class Ib (Lidocaine, Mexiletine):
Kinetics: Very rapid association and dissociation kinetics ( τ < 0.5 seconds \tau < 0.5\text{ seconds} τ < 0.5 seconds ).
Electrophysiology: Bind with high affinity to sodium channels in the open and inactivated states , dissociating rapidly during diastole. In normal cardiac tissue at resting membrane potentials ( − 90 mV -90\text{ mV} − 90 mV ), lidocaine has minimal effect. However, in depolarized, ischemic, or rapidly firing ventricular myocardium (where channels spend extended time in the inactivated state), lidocaine binding is intense, suppressing Phase 0 and reducing abnormal ventricular automaticity. It shortens Phase 3 repolarization and APD by blocking late persistent sodium currents ( I Na,late I_{\text{Na,late}} I Na,late ). Class Ib agents are completely ineffective for supraventricular arrhythmias because atrial action potentials have short plateau phases, precluding significant channel inactivation.
Class Ic (Flecainide, Propafenone):
Kinetics: Very slow association and dissociation kinetics ( τ > 10 − 30 seconds \tau > 10 - 30\text{ seconds} τ > 10 − 30 seconds ).
Electrophysiology: Because dissociation is remarkably slow, channels accumulate block from cycle to cycle even at physiological heart rates. They cause marked depression of Phase 0 d V / d t max dV/dt_{\max} d V / d t m a x , profoundly slowing intracardiac conduction and broadening the QRS complex across all heart rates, with virtually no effect on APD or QT duration. In patients with prior myocardial infarction or structural heart disease, Class Ic agents dramatically increase the risk of lethal re-entrant ventricular tachycardias (demonstrated in the Cardiac Arrhythmia Suppression Trial, CAST) and are strictly contraindicated in structural cardiac pathology.
Class II: Beta-Adrenergic Antagonists
Class II agents competitively antagonize catecholamine binding at cardiac beta-1 receptors. By reducing cAMP \text{cAMP} cAMP and PKA activity, they decrease the slope of Phase 4 spontaneous diastolic depolarization in the sinoatrial (SA) node and suppress calcium currents ( I Ca,L I_{\text{Ca,L}} I Ca,L ) in the atrioventricular (AV) node. This prolongs AV nodal conduction time and refractory periods, effectively terminating AV nodal re-entrant tachycardias and slowing ventricular response in atrial fibrillation.
Class III: Potassium Channel Blockers
Class III drugs block the delayed rectifier potassium currents responsible for cardiac repolarization, predominantly the rapid ( I Kr I_{\text{Kr}} I Kr ) and slow ( I Ks I_{\text{Ks}} I Ks ) components. This delays Phase 3 repolarization, prolonging the APD and ERP across atrial and ventricular myocytes. On surface ECG, this corresponds to QT interval prolongation .
Amiodarone
Amiodarone is a benzofuran derivative containing two iodine atoms that structurally resembles thyroxine ( T 4 T_4 T 4 ). Although classified under Class III, it exhibits electrophysiological properties across all four Vaughan-Williams classes :
Class I: Blocks inactivated sodium channels (fast Phase 0 kinetics).
Class II: Non-competitively antagonizes α \alpha α and β \beta β adrenoceptors.
Class III: Blocks delayed rectifier potassium channels ( I Kr , I Ks I_{\text{Kr}}, I_{\text{Ks}} I Kr , I Ks ), prolonging APD and ERP.
Class IV: Blocks L-type calcium channels, depressing sinus and AV nodal conduction. [ AMIOARONE PHARMACOKINETICS & TOXICITY ]
- |
- +--------------------------------+--------------------------------+
- | |
- [ PHARMACOKINETIC PROFILE ] [ MULTI-ORGAN TOXICITY ]
- Extreme Lipophilicity - Pulmonary: Interstitial alveolitis,
- Volume of Distribution ~60 L/kg (20-200) fibrosis (O2 toxicity hazard)
- Elimination Half-Life: 30 to 60 days - Thyroid: Hypothyroidism (Wolff-Chaikoff)
- Hepatic CYP3A4 / CYP2C8 Metabolism or Thyrotoxicosis (Jod-Basedow)
- Active Metabolite: Desethylamiodarone (DEA) - Corneal Microdeposits (>90% patients)
- Potent CYP2C9, CYP3A4, & P-gp Inhibitor - Dermatologic: Blue-grey slate skin
- (Doubles serum digoxin & warfarin levels) - Cardiac: Bradycardia, AV block
- (Very low Torsades risk: <1%)
Unique Electrophysiological Safety: Despite marked QTc prolongation, the incidence of torsades de pointes with amiodarone is exceptionally low ( < 1 % <1\% < 1% , far lower than sotalol, quinidine, or ibutilide). This protection is conferred by concurrent L-type calcium and beta-blockade, which suppresses early afterdepolarizations (EADs), coupled with uniform prolongation of refractoriness across the endocardium, myocardium (M-cells), and epicardium, minimizing transmural dispersion of repolarization.
Complex Pharmacokinetics: Amiodarone is exceptionally lipophilic, extensively sequestered in adipose tissue, skeletal muscle, liver, and lung parenchyma. Its volume of distribution ( V d V_d V d ) exceeds 5000 L 5000\text{ L} 5000 L ( > 60 L/kg >60\text{ L/kg} > 60 L/kg ). Following chronic therapy, its terminal elimination half-life ranges from 30 to 60 days . Hepatic metabolism generates the active metabolite desethylamiodarone (DEA). It is a potent inhibitor of cytochrome P450 enzymes (CYP2C9, CYP3A4) and P-glycoprotein, doubling circulating serum levels of warfarin and digoxin.
Organ-Specific Adverse Effects:
Pulmonary Fibrosis: Affects up to 5% to 10% of patients on chronic therapy; causes toxic lymphocytic and eosinophilic alveolitis progressing to irreversible pulmonary fibrosis. Perioperatively, exposure to high fractions of inspired oxygen ( F i O 2 > 0.50 Fi\text{O}_2 > 0.50 F i O 2 > 0.50 ) triggers massive free radical generation, precipitating acute fulminant pneumonitis and ARDS.
Thyroid Dysfunction: Each 200-mg tablet contains ~75 mg of organic iodine, releasing ~6 mg of free iodide daily (hundreds of times the daily requirement). It can induce amiodarone-induced hypothyroidism (AIH) via the persistent Wolff-Chaikoff effect (inhibition of thyroid hormone synthesis) or amiodarone-induced thyrotoxicosis (AIT) , either via iodine-induced hyperthyroidism in underlying goiter (AIT-1 / Jod-Basedow) or destructive autoimmune thyroiditis (AIT-2).
Ophthalmologic: Bilateral benign corneal microdeposits (vortex keratopathy) develop in > 90 % >90\% > 90% of patients within months; optic neuropathy/neuritis can cause permanent visual loss.
Dermatologic: Slate blue-grey cutaneous hyperpigmentation in sun-exposed areas and severe photosensitivity.
Hepatic: Asymptomatic transaminase elevations in up to 25%; rarely cirrhosis.
Class IV: Non-Dihydropyridine Calcium Channel Blockers
Class IV agents ( verapamil and diltiazem ) selectively bind the alpha-1 subunit of L-type voltage-gated calcium channels ( C a V 1.2 Ca_V1.2 C a V 1.2 ) in cardiac nodal and conducting tissue. They slow Phase 0 depolarization in the SA and AV nodes, prolong AV nodal conduction time and refractory periods, and depress myocardial inotropy. They are first-line for rate control of supraventricular tachyarrhythmias, but are strictly contraindicated in severe heart failure with reduced ejection fraction (HFrEF) and in Wolff-Parkinson-White (WPW) syndrome with pre-excited atrial fibrillation (blocking the AV node diverts all conduction over the accessory bypass tract, provoking fatal ventricular fibrillation).
- 2. Atypical Antiarrhythmics: Adenosine and Digoxin
- Adenosine
Molecular Mechanism: Adenosine is an endogenous purine nucleoside that binds to cardiac A 1 A_1 A 1 adenosine receptors located in the SA node, atrial myocardium, and AV node. The A 1 A_1 A 1 receptor couples to the G i G_i G i protein :
The liberated G β γ G_{\beta\gamma} G β γ dimer directly activates acetylcholine/adenosine-sensitive inward-rectifying potassium channels ( I K,Ado I_{\text{K,Ado}} I K,Ado ) , driving potassium efflux and profound cellular hyperpolarization.
The G α i G_{\alpha i} G α i subunit inhibits adenylyl cyclase, lowering cAMP \text{cAMP} cAMP and suppressing L-type calcium current ( I Ca,L I_{\text{Ca,L}} I Ca,L ).
The combination of hyperpolarization and reduced calcium influx produces transient, complete electrophysiological conduction block at the AV node for several seconds.
Clinical Utility: The first-line agent for the immediate termination of paroxysmal supraventricular tachycardias involving the AV node in their re-entrant circuit (AVNRT and orthodromic AVRT).
Ultra-Short Pharmacokinetics: Adenosine is rapidly eliminated from the vascular compartment through carrier-mediated cellular uptake into erythrocytes and vascular endothelial cells, where it is converted to inosine by adenosine deaminase (ADA) or phosphorylated to AMP by adenosine kinase. Its plasma elimination half-life is < 10 seconds <10\text{ seconds} < 10 seconds . To be effective, it must be administered as a rapid intravenous bolus through a large, proximal vein (antecubital or central line) immediately followed by a rapid 20-mL saline flush.
Drug Interactions and Clinical Traps:
Methylxanthines (Caffeine, Theophylline, Aminophylline): Competitive antagonists at the A 1 A_1 A 1 receptor; significantly higher doses of adenosine are required for efficacy.
Dipyridamole: Inhibits the cellular nucleoside uptake transporter, blocking clearance and prolonging adenosine action; the dose must be reduced to one-third or one-quarter (e.g., 1.5 - 3.0 mg).
Denervated Hearts (Cardiac Transplants): Exhibit marked hypersensitivity to adenosine due to up-regulated postsynaptic A 1 A_1 A 1 receptors; initial doses should be reduced to 3 mg to prevent prolonged asystolic arrest.
Severe Asthma: Adenosine stimulates bronchial A 2 B A_{2B} A 2 B and A 3 A_3 A 3 receptors, potentially triggering severe, acute bronchospasm; it is relatively contraindicated in severe reactive airway disease.
Digoxin (Cardiac Glycoside)
Molecular Mechanism: Digoxin binds selectively and reversibly to the extracellular domain of the sarcolemmal Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase pump , inhibiting its active enzymatic transport. Intracellular sodium ( [ N a + ] i [Na^+]_i [ N a + ] i ) rises, reducing the trans-sarcolemmal sodium concentration gradient. This attenuates the driving force for the 3 Na + / C a 2 + 3\text{Na}^+/Ca^{2+} 3 Na + / C a 2 + antiporter (NCX) , slowing calcium extrusion and elevating intracellular free calcium. This calcium is sequestered into the SR by SERCA2a, augmenting subsequent systolic calcium release and delivering moderate positive inotropy .
Autonomic Action: Central vagomimetic effect; stimulates the nodose ganglion and vagal nuclei in the medulla, increasing parasympathetic efferent outflow to the SA and AV nodes. This prolongs AV nodal refractoriness and slows conduction velocity, making it valuable for ventricular rate control in chronic atrial fibrillation.
Narrow Therapeutic Index: Therapeutic serum concentration is 0.5 − 2.0 ng/mL 0.5 - 2.0\text{ ng/mL} 0.5 − 2.0 ng/mL (modern target for heart failure is 0.5 − 0.9 ng/mL 0.5 - 0.9\text{ ng/mL} 0.5 − 0.9 ng/mL ). Toxicity occurs readily at levels > 2.0 ng/mL >2.0\text{ ng/mL} > 2.0 ng/mL .
Electrolyte Sensitization: Hypokalemia, hypomagnesemia, and hypercalcemia profoundly aggravate toxicity. Extracellular K + K^+ K + and digoxin compete for the same binding site on the Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase pump; hypokalemia increases digoxin binding and toxicity .
Manifestations of Toxicity:
Gastrointestinal: Anorexia, nausea, vomiting, abdominal pain.
Neurological: Confusion, weakness, characteristic yellow-green chromatic visual halos ( xanthopsia ).
Cardiac Arrhythmias: Frequent premature ventricular contractions (PVCs), paroxysmal atrial tachycardia with variable AV block, junctional escape rhythms, and pathognomonic bidirectional ventricular tachycardia .
Treatment: Immediate administration of Digoxin-specific Fab antibody fragments (DigiFab) , gentle correction of hypokalemia and hypomagnesemia, and temporary cardiac pacing for high-grade AV block. Dialysis is ineffective due to a large volume of distribution ( V d ≈ 5 − 7 L/kg V_d \approx 5 - 7\text{ L/kg} V d ≈ 5 − 7 L/kg ). Avoid cardioversion if possible, as it may precipitate intractable ventricular fibrillation.
- 3. Parenteral Antihypertensive Agents and Vasodilators [ PARENTERAL VASODILATOR PATHWAYS ]
- |
- +-------------------------------+-------------------------------+
- | |
- [ NITROVASODILATORS ] [ CALCIUM CHANNEL BLOCKERS ]
- Sodium Nitroprusside (SNP) & Nitroglycerin (GTN) Clevidipine & Nicardipine
- | |
- Release Nitric Oxide (NO) Block L-type Voltage-Gated Ca2+ Channels
- SNP: Spontaneous, Non-Enzymatic - Clevidipine: Esterase Cleavage (t_1/2 = 1-2 min)
- GTN: Requires Aldehyde Dehydrogenase-2 (ALDH2) - High Vascular Smooth Muscle Selectivity
- | |
- Stimulates Soluble Guanylyl Cyclase (sGC) Decreases Inward Ca2+ Influx
- | |
- Elevates Intracellular cGMP Inhibits MLCK Activation
- | |
- Activates Protein Kinase G (PKG) Direct Arterial Vasodilation
- | Decreased SVR without Myocardial Depression
- Dephosphorylates Myosin Light Chains & Extrudes Ca2+
- |
- Balanced Arterial & Venous Dilation (SNP)
- Predominant Venodilation & Preload Reduction (GTN)
- Sodium Nitroprusside (SNP)
Chemical Structure: An inorganic complex containing a central ferrous iron ( F e 2 + Fe^{2+} F e 2 + ) atom coordinated with five cyanide anions ( C N − CN^- C N − ) and one nitrosyl group ( N O + NO^+ N O + ): Na 2 [ F e ( CN ) 5 NO ] \text{Na}_2[Fe(\text{CN})_5\text{NO}] Na 2 [ F e ( CN ) 5 NO ]
Mechanism: SNP acts as a direct nitric oxide donor . Upon exposure to sulfhydryl groups on erythrocyte membranes and vascular tissue, it breaks down spontaneously and non-enzymatically , releasing free nitric oxide (NO). NO diffuses into vascular smooth muscle to activate soluble guanylyl cyclase (sGC), generating cyclic guanosine monophosphate ( cGMP \text{cGMP} cGMP ) and activating protein kinase G (PKG). PKG dephosphorylates myosin light chains and drives intracellular calcium extrusion, producing instantaneous, balanced arterial and venous dilation .
Metabolism and Cyanide Toxicity:
Each molecule of SNP releases five cyanide ions . In the liver and kidneys, the mitochondrial enzyme rhodanese (thiosulfate sulfurtransferase) detoxifies cyanide by transferring a sulfur atom from endogenous thiosulfate to cyanide, forming water-soluble, non-toxic thiocyanate , which is cleared by the kidneys.
Cyanide Poisoning Cascade: When SNP is infused at high rates ( > 2 mcg/kg/min >2\text{ mcg/kg/min} > 2 mcg/kg/min ) or for prolonged durations ( > 24 hours >24\text{ hours} > 24 hours ), endogenous thiosulfate stores are rapidly exhausted. Free cyanide binds with extreme affinity to ferric iron ( F e 3 + Fe^{3+} F e 3 + ) within cytochrome c oxidase (Complex IV) of the mitochondrial respiratory chain, completely halting aerobic oxidative phosphorylation. Cells starve of ATP and are forced into anaerobic glycolysis.
Diagnostic Hallmarks of Cyanide Toxicity:
Tachyphylaxis: Rapidly escalating dose requirements of SNP to achieve the same target blood pressure.
Unexplained Metabolic Lactic Acidosis: Progressive, refractory high anion gap acidosis.
Elevated Mixed Venous Oxygen Saturation ( S v O 2 > 85 − 90 % Sv\text{O}_2 > 85 - 90\% S v O 2 > 85 − 90% ): Tissues are poisoned and cannot extract oxygen from circulating oxyhemoglobin, causing arterialization of venous blood (bright red venous blood).
Cyanide Antidote Protocol:
Hydroxocobalamin (5 g IV over 15 minutes): The modern first-line antidote. Its cobalt center binds cyanide with greater affinity than cytochrome oxidase, forming non-toxic cyanocobalamin (vitamin B 12 B_{12} B 12 ) , which is safely excreted in urine.
Sodium Thiosulfate (12.5 g IV): Supplies exogenous sulfur donors for the rhodanese pathway.
Sodium Nitrite: Oxidizes hemoglobin F e 2 + Fe^{2+} F e 2 + to methemoglobin ( F e 3 + Fe^{3+} F e 3 + ), which acts as a chemical decoy to pull cyanide off cytochrome oxidase (use cautiously perioperatively due to impaired oxygen delivery).
Nitroglycerin (Glyceryl Trinitrate, GTN)
Mechanism: Unlike SNP, nitroglycerin is a prodrug that requires enzymatic bioactivation by mitochondrial aldehyde dehydrogenase-2 (ALDH2) in vascular endothelial and smooth muscle cells, generating NO and triggering the cGMP-PKG \text{cGMP-PKG} cGMP-PKG pathway.
Hemodynamic Actions: At low to moderate clinical doses ( 0.1 − 2.0 mcg/kg/min 0.1 - 2.0\text{ mcg/kg/min} 0.1 − 2.0 mcg/kg/min ), GTN is a predominant venous capacitance dilator . By dilating large systemic veins, it pools blood in the periphery, decreasing venous return, left ventricular end-diastolic volume, and wall stress (reducing myocardial preload and M V O 2 MVO_2 M V O 2 ). It also dilates large epicardial coronary arteries, relieving coronary vasospasm and redistributing blood flow to ischemic subendocardial tissue. Only at high doses ( > 2 − 3 mcg/kg/min >2 - 3\text{ mcg/kg/min} > 2 − 3 mcg/kg/min ) does significant arteriolar dilation occur.
Nitrate Tolerance (Tachyphylaxis): Continuous infusion for > 24 − 48 hours >24 - 48\text{ hours} > 24 − 48 hours leads to complete loss of hemodynamic efficacy. This tolerance is caused by depletion of intracellular sulfhydryl groups, oxidative inactivation of ALDH2 by reactive oxygen species, and neurohormonal counter-regulation (activation of the renin-angiotensin system). Prevention requires a daily nitrate-free interval of 8 to 12 hours .
Hydralazine
Mechanism: Direct-acting arteriolar smooth muscle relaxant that produces membrane hyperpolarization and inhibits IP 3 \text{IP}_3 IP 3 -mediated calcium release from the sarcoplasmic reticulum. It exerts virtually no effect on venous capacitance vessels.
Pharmacokinetics and Limitations: Hydralazine has an unpredictable, delayed onset ( 15 to 20 minutes ) and a prolonged duration of action ( 2 to 6 hours ), precluding fine titration in acute perioperative crises. It provokes intense reflex sympathetic baroreceptor activation , causing marked tachycardia, increased stroke volume, and fluid retention, which can precipitate acute myocardial ischemia in patients with coronary artery disease.
Toxicity: Chronic therapy is associated with drug-induced systemic lupus erythematosus (SLE) , particularly in slow hepatic acetylators.
- 4. Short-Acting Beta-Antagonists and Dihydropyridines
- Esmolol
Pharmacology: Ultra-short-acting, cardioselective β 1 \beta_1 β 1 -adrenergic antagonist with minimal intrinsic sympathomimetic activity and no membrane-stabilizing effects.
Metabolism: Contains an internal ester linkage that is rapidly hydrolyzed by cytoplasmic esterases located in red blood cells (erythrocytes). It is not dependent on hepatic metabolism or plasma pseudocholinesterase.
Pharmacokinetics: Peak therapeutic effect occurs within 2 to 5 minutes following an intravenous bolus ( 0.5 mg/kg 0.5\text{ mg/kg} 0.5 mg/kg ); its elimination half-life is 9 minutes , and full hemodynamic recovery occurs within 20 to 30 minutes of cessation. It is the premier agent for blunting acute, transient sympathetic surges associated with direct laryngoscopy, tracheal intubation, surgical incision, and emergence from anaesthesia.
Labetalol
Pharmacology: Combined competitive α 1 \alpha_1 α 1 and non-selective β 1 / β 2 \beta_1/\beta_2 β 1 / β 2 antagonist . It possesses intrinsic sympathomimetic activity at β 2 \beta_2 β 2 receptors.
Blockade Ratio: The ratio of α \alpha α to β \beta β antagonism is approximately 1:7 for intravenous administration and 1:3 for oral administration .
Hemodynamics: Arteriolar vasodilation via α 1 \alpha_1 α 1 blockade lowers systemic vascular resistance, while concurrent β 1 \beta_1 β 1 blockade prevents reflex baroreceptor tachycardia, maintaining cardiac output and reducing myocardial oxygen demand.
Clevidipine
Pharmacology: A third-generation, vascular-selective dihydropyridine calcium channel blocker . It selectively inhibits L-type calcium channels on arterial smooth muscle, decreasing SVR and MAP without negative inotropy, prolongation of AV conduction, or reflex tachycardia.
Metabolism and Rapid Recovery: Formulated with an ester side chain that is cleaved within seconds by non-specific blood and tissue esterases . Its initial distribution half-life is 1 minute , and its terminal elimination half-life is 1 to 2 minutes .
Formulation: Insoluble in water; formulated as a sterile 20% oil-in-water lipid emulsion containing soybean oil and egg yolk phospholipids ( 2.0 kcal/mL 2.0\text{ kcal/mL} 2.0 kcal/mL ). It requires strict aseptic technique, and infusion bottles/lines must be discarded after 12 hours. It is contraindicated in patients with severe allergy to soy or egg products and in severe lipid metabolism disorders.
5. Perioperative Management of ACE Inhibitors and ARBs
Chronic inhibition of the renin-angiotensin-aldosterone system (RAAS) with Angiotensin-Converting Enzyme (ACE) Inhibitors (e.g., ramipril, enalapril, lisinopril) or Angiotensin Receptor Blockers (ARBs) (e.g., losartan, valsartan, candesartan) presents a unique challenge under general anaesthesia. [ MECHANISM OF INDUCTION VASOPLEGIA ]
- |
- +-----------------------------+-----------------------------+
- | |
- [ NORMAL AWAKE STATE ] [ GENERAL ANAESTHESIA ]
- Blood Pressure maintained by three Anaesthetic agents suppress
- complementary homeostatic systems: Sympathetic Nervous System
- 1. Sympathetic Nervous System |
- 2. Renin-Angiotensin-Aldosterone System v
- 3. Vasopressinergic System Patient with chronic ACEi / ARB therapy
- has paralyzed RAAS axis
- |
- v
- Homeostasis depends SOLELY on
- Vasopressin System (third pillar)
- |
- v
- [ PROFOUND REFRACTORY VASOPLEGIA ]
- Massive drop in SVR and MAP
- Unresponsive to fluids and pure alpha-1 agonists
- Clinical Management and Rescue Algorithm
Withholding Guidance: The 2022 ESC guideline on non-cardiac surgery (endorsed by ESAIC) states that, in patients without heart failure, withholding RAAS inhibitors on the day of surgery should be considered to prevent perioperative hypotension. The 2024 STOP-or-NOT trial found no difference in major complications between stopping 48 hours beforehand and continuing, although continuation produced more intraoperative hypotension; decisions are therefore individualised.
Rescue Therapy for Refractory Vasoplegia: When severe post-induction vasoplegia develops in patients who took an ACEi/ARB on the morning of surgery:
Standard volume expansion and pure α 1 \alpha_1 α 1 agonists (phenylephrine) often fail due to profound uncoupling of vascular tone.
Norepinephrine infusion should be initiated promptly.
Arginine Vasopressin (AVP): The definitive targeted rescue agent. Administered as an IV bolus of 1 to 2 units followed by an infusion of 0.01 − 0.04 units/min 0.01 - 0.04\text{ units/min} 0.01 − 0.04 units/min , restoring vascular tone by activating the third, unblocked homeostatic axis.
Methylene Blue: In cases of catecholamine- and vasopressin-resistant vasoplegia, methylene blue ( 1.5 − 2.0 mg/kg 1.5 - 2.0\text{ mg/kg} 1.5 − 2.0 mg/kg IV over 20 to 60 minutes) acts as an inhibitor of both endothelial inducible nitric oxide synthase (iNOS) and soluble guanylyl cyclase (sGC), terminating excessive cGMP \text{cGMP} cGMP accumulation and restoring vascular smooth muscle responsiveness.